secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001641172-25-024190
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics enters separation agreement with ex-President Boris Minev; $287,500 in payments
--------------------------------------------------------------------------------

- Dr. Boris Minev ceased as President, Medical & Scientific Affairs and Section 16 officer effective July 29, 2025.
- Separation agreement provides $100,000 negotiated bonus for NNV1 and SNV1 IND approvals and $187,500 severance over 6 months.
- Company will pay COBRA premiums for 6 months.
- Agreement includes standard release of claims and non-disparagement; effective after 7-day revocation period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225024190/0001641172-25-024190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225024190/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-024190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer